Title : A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Pub. Date : 2014 Apr 15

PMID : 24474568






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Efavirenz, a potent inducer of CYP3A4, resulted in increased exposure of N-desethyl sunitinib, whereas ritonavir caused decreased exposure of the metabolite. efavirenz cytochrome P450 family 3 subfamily A member 4 Homo sapiens